Vertex Stock Slides On Schering's Positive Data

October 2007
Bioworld Week;10/22/2007, Vol. 15 Issue 43, p5
The article reports that the shares of Vertex Pharmaceuticals Inc. of Cambridge, Massachusetts has dropped by 13.2% due to Phase II clinical trial data from Kenilworth, New Jersey-based Schering-Plough Corp.'s oral hepatitis C protease inhibitor. Schering's boceprevir combined with Pegintron and Rebetol has achieved greater virologic response with up to 79% of patients with undetectable virus at 12 weeks, while Vertex's telaprevir combined with pegylated interfern and ribavirin showed only 70%.


Related Articles

  • HCV Vaccines, TLRs Advance Away from Protease Spotlight. Morrison, Trista // BioWorld Today;11/2/2009, Vol. 20 Issue 211, p3 

    The article discusses the highlights of the annual meeting of the American Association for the Study of Liver Disease (AASLD). Protease inhibitors were the main attraction at the annual meeting, including telaprevir from Vertex Pharmaceutical inc. and boceprevir from Schering-Plough Corp....

  • Acadesine: AICA Riboside, ARA 100, Arasine, GP 1 110.  // Drugs in R&D;2008, Vol. 9 Issue 3, p169 

    Acadesine is an adenosine receptor agonist (ARA) in development for the treatment of ischaemia-reperfusion injury and chronic lymphocytic leukaemia. Schering-Plough is developing the compound as a cardioprotective agent in ischaemia-reperfusion injury. Avancell and Protherics are co-developing...

  • Clinical Trials News.  // Applied Clinical Trials;Aug2004, Vol. 13 Issue 8, p15 

    Presents news updates on clinical trials in the U.S., compiled as of August 2004. Orphan drug designation received by Medarex for its CTLA-4 antibody MDX-010 for treatment of melanoma; Effectiveness of Schering-Plough's rheumatoid arthritis treatment Remicade; Results of the phase III Merck...

  • Serious Doubts on Safety and Efficacy of CCR5 Antagonists. Horster, S.; Goebel, F. // Infection;Apr2006, Vol. 34 Issue 2, p110 

    The article reports on the separate clinical trials involving CCR5 antagonists, GlaxoSmithKline's aplaviroc, Pfizer's maraviroc and Schering-Plough's vicriviroc, in patients with AIDS. In healthy volunteers, the substances exhibited an efficacy to prevent the propagation of virus strains with...

  • MIGENIX INITIATES ENROLLMENT IN PHASE IIB HEPATITIS TRIAL.  // Worldwide Biotech;Jan2006, Vol. 18 Issue 1, p1 

    The article reports on the launch of a Phase IIb combination therapy clinical trial of celgosivir by Migenix Inc. which aimed to develop a treatment of chronic hepatitis C virus as of January 2006. Migenix CEO Jim DeMesa offered a statement on the drug. The study is an evaluation of the drug in...

  • Vertex: next-generation hepatitis drugs within reach.  // PharmaWatch: Biotechnology;Jul2006, Vol. 5 Issue 7, p27 

    The article features VX-950, a protease inhibitor drug considered as a new hepatitis C drug candidate developed by Vertex Pharmaceuticals Inc. The new drug has to undergo phase II clinical trial to measure its effectiveness if combined with the current standard care, its optimal treatment...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Apr2008, Vol. 22 Issue 4, p345 

    The article offers news briefs on antiviral agents. Vertex Pharmaceuticals Inc. and Tibotec have started screening patients for a Phase 3 clinical trial called the Advance study. The U.S. Food & Drug Adminstration has added information about hepatotoxicity to the warnings section of darunavir...

  • Vertex Slides On Competitor Schering's Positive HCV Data.  // BioWorld Today;10/19/2007, Vol. 18 Issue 204, p3 

    The article reports on the decline in the shares of Vertex Pharmaceuticals Inc. following the release of data from the Phase II trial of the oral hepatitis C protease inhibitor by Schering-Plough Corp. In the study by Schering-Plough, a high rate of virologic response was obtained from hepatitis...

  • Drug firms focus orally active protease inhibitors for hepatitis C.  // Medical Marketing & Media;Aug97, Vol. 32 Issue 8, p26 

    Reports on the involvement of drug companies in search for orally active protease inhibitors to treat hepatitis C. Schering-Plough's agreement with Corvas International; Eli Lilly's collaboration with the research firm Vertex Pharmaceuticals.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics